These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34257747)

  • 1. Peripheral Oxidation Markers in Down Syndrome Patients: The Better and the Worse.
    Szwajgier D; Baranowska-Wójcik E; Grzelczyk J; Żukiewicz-Sobczak W
    Dis Markers; 2021; 2021():5581139. PubMed ID: 34257747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.
    Cenini G; Dowling AL; Beckett TL; Barone E; Mancuso C; Murphy MP; Levine H; Lott IT; Schmitt FA; Butterfield DA; Head E
    Biochim Biophys Acta; 2012 Feb; 1822(2):130-8. PubMed ID: 22009041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased oxidative stress biomarkers in the saliva of Down syndrome patients.
    Komatsu T; Duckyoung Y; Ito A; Kurosawa K; Maehata Y; Kubodera T; Ikeda M; Lee MC
    Arch Oral Biol; 2013 Sep; 58(9):1246-50. PubMed ID: 23714170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress and metabolism at rest and during exercise in persons with Down syndrome.
    Flore P; Bricout VA; van Biesen D; Guinot M; Laporte F; Pépin JL; Eberhard Y; Favre-Juvin A; Wuyam B; van de Vliet P; Faure P
    Eur J Cardiovasc Prev Rehabil; 2008 Feb; 15(1):35-42. PubMed ID: 18277183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid peroxidation in Down syndrome caused by regular trisomy 21, trisomy 21 by Robertsonian translocation and mosaic trisomy 21.
    Casado A; López-Fernández ME; Ruíz R
    Clin Chem Lab Med; 2007; 45(1):59-62. PubMed ID: 17243916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress and Down syndrome. Do antioxidants play a role in therapy?
    Muchová J; Žitňanová I; Ďuračková Z
    Physiol Res; 2014; 63(5):535-42. PubMed ID: 24908086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The exercise redox paradigm in the Down's syndrome: improvements in motor function and increases in blood oxidative status in young adults.
    Aguiar AS; Tuon T; Albuquerque MM; Rocha GS; Speck AE; Araújo JC; Dafré AL; Prediger RD; Pinho RA
    J Neural Transm (Vienna); 2008 Dec; 115(12):1643-50. PubMed ID: 18795225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects.
    Tiano L; Padella L; Carnevali P; Gabrielli O; Bruge F; Principi F; Littarru GP
    Biofactors; 2008; 32(1-4):161-7. PubMed ID: 19096112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down syndrome--genetic and nutritional aspects of accompanying disorders.
    Mazurek D; Wyka J
    Rocz Panstw Zakl Hig; 2015; 66(3):189-94. PubMed ID: 26400113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered glutamate uptake in peripheral tissues from Down syndrome patients.
    Begni B; Brighina L; Fumagalli L; Andreoni S; Castelli E; Francesconi C; Del Bo R; Bresolin N; Ferrarese C
    Neurosci Lett; 2003 Jun; 343(2):73-6. PubMed ID: 12759167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of urinary biomarkers of oxidative/nitrosative stress in adolescents and adults with Down syndrome.
    Campos C; Guzmán R; López-Fernández E; Casado A
    Biochim Biophys Acta; 2011 Jul; 1812(7):760-8. PubMed ID: 21447387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidant intervention attenuates oxidative stress in children and teenagers with Down syndrome.
    Parisotto EB; Garlet TR; Cavalli VL; Zamoner A; da Rosa JS; Bastos J; Micke GA; Fröde TS; Pedrosa RC; Wilhelm Filho D
    Res Dev Disabil; 2014 Jun; 35(6):1228-36. PubMed ID: 24685938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of extracellular adenine nucleotides hydrolysis in platelets and biomarkers of oxidative stress in Down syndrome individuals.
    Ferreira M; Rodrigues R; Motta E; Debom G; Soares F; de Mattos Bda S; Machado C; Stefanello FM; da Silva TM; Martins CC; Dalenogare D; Morsch VM; Braganhol E; Spanevello RM
    Biomed Pharmacother; 2015 Aug; 74():200-5. PubMed ID: 26349985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid.
    Perluigi M; di Domenico F; Fiorini A; Cocciolo A; Giorgi A; Foppoli C; Butterfield DA; Giorlandino M; Giorlandino C; Schininà ME; Coccia R
    Proteomics Clin Appl; 2011 Apr; 5(3-4):167-78. PubMed ID: 21360684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal biomarkers in Down syndrome and Alzheimer's disease.
    Hamlett ED; Ledreux A; Potter H; Chial HJ; Patterson D; Espinosa JM; Bettcher BM; Granholm AC
    Free Radic Biol Med; 2018 Jan; 114():110-121. PubMed ID: 28882786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of the benefit of an antioxidant therapy in children and teenagers with Down syndrome.
    Parisotto EB; Giaretta AG; Zamoner A; Moreira EA; Fröde TS; Pedrosa RC; Filho DW
    Res Dev Disabil; 2015; 45-46():14-20. PubMed ID: 26207872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic oxidative stress in children and teenagers with Down syndrome.
    Garlet TR; Parisotto EB; de Medeiros Gda S; Pereira LC; Moreira EA; Dalmarco EM; Dalmarco JB; Wilhelm Filho D
    Life Sci; 2013 Oct; 93(16):558-63. PubMed ID: 24004546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.
    Perluigi M; Di Domenico F; Buttterfield DA
    Proteomics Clin Appl; 2014 Feb; 8(1-2):73-85. PubMed ID: 24259517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.
    Di Domenico F; Coccia R; Cocciolo A; Murphy MP; Cenini G; Head E; Butterfield DA; Giorgi A; Schinina ME; Mancuso C; Cini C; Perluigi M
    Biochim Biophys Acta; 2013 Aug; 1832(8):1249-59. PubMed ID: 23603808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.
    Tolun AA; Scarbrough PM; Zhang H; McKillop JA; Wang F; Kishnani PS; Millington DS; Young SP; Il'yasova D
    Ann Epidemiol; 2012 Dec; 22(12):892-4. PubMed ID: 23063134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.